Squamous cell carcinoma of the head and neck represents a group of cancers that begin in the thin, flat cells lining the moist surfaces inside the mouth, throat, voice box, nose, and sinuses. Treatment approaches focus on removing or destroying cancer while preserving essential functions like speaking, swallowing, and breathing, with outcomes depending heavily on how early the disease is detected and the patient’s overall health.

Fighting Cancer While Preserving Quality of Life

When someone receives a diagnosis of squamous cell carcinoma in the head and neck area, the main goals of treatment extend beyond simply eliminating the cancer. Doctors work to control symptoms, slow disease progression, and maintain or improve the person’s ability to perform daily activities that most of us take for granted. These include speaking clearly, eating comfortably, breathing easily, and maintaining facial appearance and expression.

The treatment plan for head and neck squamous cell carcinoma varies significantly based on several factors. The stage of the cancer—whether it’s confined to a small area or has spread to lymph nodes or distant parts of the body—plays a crucial role in determining the approach. The exact location of the tumor matters too, as cancers in the mouth may be treated differently than those in the throat or voice box. Additionally, a patient’s age, overall health, ability to tolerate certain treatments, and whether the cancer is related to human papillomavirus (HPV) infection all influence treatment decisions.^[4][6]

Medical professionals follow established treatment guidelines approved by medical societies and cancer organizations. At the same time, researchers worldwide are testing promising new therapies through clinical trials. These studies aim to find treatments that work better than current options or cause fewer side effects. Understanding both standard treatments and experimental approaches helps patients and their families make informed decisions about care.

Established Treatment Methods for Head and Neck Cancer

Standard treatment for squamous cell carcinoma of the head and neck typically involves a combination of approaches rather than relying on a single method. For cancers located in the oral cavity—the mouth area including the lips, tongue, gums, and inner cheeks—doctors generally recommend surgery as the first step. This surgical approach removes the tumor along with some surrounding healthy tissue to ensure all cancer cells are eliminated. Often, lymph nodes in the neck are also removed, either on one side or both sides, depending on how likely the cancer is to have spread.^[4][6]

Following surgery for oral cavity cancers, many patients receive additional treatment to reduce the risk of cancer returning. This typically consists of radiation therapy, which uses high-energy beams to destroy any remaining cancer cells, combined with chemotherapy, which uses drugs to kill cancer cells throughout the body. This combined approach is called chemoradiotherapy or CRT. The chemotherapy drugs most commonly used include platinum-based compounds like cisplatin, which work by damaging the DNA inside cancer cells so they cannot multiply.^[4]

For cancers that originate in the pharynx (throat) or larynx (voice box), treatment often begins with chemoradiotherapy rather than surgery. This approach can be equally effective while potentially preserving the structure and function of these organs, which are essential for speech and swallowing. The radiation is delivered in carefully calculated doses over several weeks, targeting the tumor while attempting to minimize damage to surrounding healthy tissue.^[4]

Another important drug used in standard treatment is cetuximab, a type of medication called a monoclonal antibody. Cetuximab works by targeting a specific protein called EGFR (epidermal growth factor receptor) that sits on the surface of cancer cells and helps them grow and divide. By blocking EGFR, cetuximab can slow or stop cancer growth. This medication is typically used in combination with radiation therapy for patients who cannot tolerate standard chemotherapy drugs due to other health problems or advanced age. Cetuximab is particularly useful for HPV-negative head and neck cancers where traditional chemotherapy might be too toxic.^[4][6][12]

Side effects from these treatments can be significant and affect quality of life. Surgery in the head and neck area may result in changes to appearance, difficulty speaking, or problems with swallowing. These functional changes can be temporary or permanent, depending on the extent of surgery. Radiation therapy commonly causes skin redness and irritation in the treatment area, dry mouth from damage to salivary glands, changes in taste, difficulty swallowing, and fatigue. These effects typically worsen as treatment progresses and may persist for weeks or months after completion.^[4]

Chemotherapy drugs like cisplatin can cause nausea and vomiting, kidney damage, hearing loss, and reduced blood cell counts that increase infection risk. When chemotherapy is combined with radiation, side effects often become more severe than with either treatment alone. Cetuximab may cause an acne-like skin rash, allergic reactions during infusion, and fatigue. Managing these side effects is a critical part of cancer care, often requiring medications to control symptoms and support from rehabilitation specialists.^[4]

Breakthrough Treatments Being Tested in Research Studies

Clinical trials represent hope for better treatment outcomes with fewer side effects. In recent years, one of the most significant advances in treating squamous cell carcinoma of the head and neck has been the development and approval of immunotherapy drugs. These medications work by helping the patient’s own immune system recognize and attack cancer cells more effectively.

Two specific immunotherapy drugs, pembrolizumab and nivolumab, have already received approval from regulatory authorities like the U.S. Food and Drug Administration (FDA) for treating recurrent or metastatic head and neck squamous cell carcinoma—meaning cancer that has come back after initial treatment or has spread to distant parts of the body. These drugs are called checkpoint inhibitors because they work by blocking proteins that normally prevent the immune system from attacking the body’s own cells.^[4][6][9]

The specific proteins these drugs target are called PD-1 (programmed death-1) and PD-L1 (programmed death-ligand 1). Cancer cells often produce PD-L1, which binds to PD-1 on immune cells and essentially tells them to “stand down” and not attack. By blocking this interaction, pembrolizumab and nivolumab allow the immune system’s T cells to recognize cancer cells as foreign invaders and destroy them. This mechanism differs fundamentally from chemotherapy, which directly poisons cancer cells, or radiation, which damages their DNA.^[4][6]

Pembrolizumab has been approved not only for recurrent or metastatic disease but also as a primary treatment for unresectable disease—cancer that cannot be removed by surgery. Clinical trials have shown that combining pembrolizumab with chemotherapy as first-line treatment for metastatic head and neck cancer can improve survival compared to chemotherapy alone in certain patients. These benefits appear particularly notable in tumors that show high levels of PD-L1 expression, which can be measured through laboratory testing of tumor samples.^[4][6][12]

Another immunotherapy drug called dostarlimab has been approved for a specific subset of patients whose tumors have a characteristic called DNA mismatch repair deficiency (dMMR). This represents a more targeted approach where genetic testing of the tumor helps identify which patients are most likely to benefit from the treatment.^[12]

Clinical trials continue to explore immunotherapy in different settings. Researchers are testing whether giving these drugs earlier in the disease course—such as before or after surgery for earlier-stage cancers—can improve cure rates and reduce the chance of cancer returning. Studies are also examining combinations of different immunotherapy drugs or combining immunotherapy with targeted therapies that block specific molecular pathways cancer cells use to grow.

Phase II and Phase III clinical trials are evaluating numerous other promising approaches. Phase II trials typically involve 50 to 300 participants and focus on determining whether a treatment shows enough efficacy to warrant further testing. Phase III trials are large studies comparing the new treatment directly against current standard treatments to determine if the new approach is superior. These trials may involve hundreds or even thousands of patients across multiple hospitals and countries.^[9]

Some innovative molecules being tested target specific genetic mutations or molecular pathways found in head and neck cancers. For example, researchers have identified mutations in genes like TP53, NOTCH1, and CDKN2A that are common in these cancers. These genes normally function as tumor suppressors, meaning they help prevent cells from growing out of control. When these genes are damaged or missing, cells can multiply uncontrollably and form tumors. Scientists are developing drugs designed to either restore the function of these damaged genes or to exploit the vulnerabilities that result from their loss.^[3][6]

Another area of active research involves drugs that target growth factor receptors beyond EGFR. Some cancers become resistant to cetuximab or never respond to it in the first place. Newer drugs are being designed to overcome this resistance or to target alternative pathways that cancer cells use to survive and grow. These include inhibitors of proteins called PIK3CA, PTEN, and others involved in cell signaling pathways that control cell division and survival.^[3]

Preliminary results from some clinical trials have shown encouraging outcomes. Patients treated with pembrolizumab or nivolumab have achieved improvements in overall survival—the length of time patients live after treatment begins—as well as progression-free survival, which measures how long patients live without their cancer getting worse. Response rates, meaning the percentage of patients whose tumors shrink significantly, have ranged from 15% to 30% in various studies, which may seem modest but represents meaningful benefit for patients who had no other effective options.^[9][12]

These immunotherapy drugs generally have a different side effect profile compared to chemotherapy. Rather than causing nausea, hair loss, and low blood counts, immune checkpoint inhibitors can cause immune-related adverse events. These occur when the activated immune system attacks normal tissues, leading to inflammation in organs such as the lungs, intestines, liver, or thyroid gland. Most of these side effects can be managed with medications that suppress the immune system, but they require careful monitoring by experienced healthcare teams.

Clinical trials for head and neck cancer are being conducted worldwide, including in the United States, Europe, and other regions. Patient eligibility for trials typically depends on factors such as the stage of cancer, whether it has been previously treated, the patient’s overall health status, and specific characteristics of their tumor such as HPV status or PD-L1 expression level. Many trials are actively recruiting participants, and patients interested in joining should discuss this option with their oncology team.^[4]

Most common treatment methods

• Surgery
  • Removal of tumors in the oral cavity (mouth) along with surrounding tissue and often lymph nodes in the neck
  • May involve partial or complete removal of structures like the tongue (glossectomy) or sections of the jawbone
  • Often followed by reconstructive surgery to restore appearance and function
• Radiation Therapy
  • Uses high-energy beams to destroy cancer cells
  • Typically delivered five days per week for six to seven weeks
  • Can be used alone or combined with chemotherapy for pharynx and larynx cancers
• Chemotherapy
  • Platinum-based drugs like cisplatin are most commonly used
  • Often combined with radiation therapy (chemoradiotherapy) after surgery or as primary treatment
  • Works by damaging DNA in cancer cells to prevent multiplication
  • Can also include 5-fluorouracil (5-FU) in combination regimens
• Targeted Therapy
  • Cetuximab blocks the EGFR protein that helps cancer cells grow
  • Used in combination with radiation therapy when chemotherapy is not suitable
  • Particularly useful for HPV-negative head and neck cancers
• Immunotherapy
  • Pembrolizumab and nivolumab block PD-1/PD-L1 proteins to help the immune system attack cancer
  • Approved for recurrent or metastatic disease
  • Pembrolizumab approved as primary treatment for unresectable cancer
  • Dostarlimab approved for tumors with DNA mismatch repair deficiency